Sign Up Now to Download a Free Research Report on

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts




Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Tranzyme, Inc.

Tranzyme shares plunged over 75% Thursday after a preliminary analysis showed
that their gastroparesis drug, TZP-102, failed to meet its primary efficacy endpoint.

Going forward ... (see research report)



RESEARCH REPORT ON Download Free Report Now


Preview Pages of Actual Equity Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on